Trikafta Cost: What You Need to Know
Trikafta, also known as eplerenone, is a prescription medication developed by Vertex Pharmaceuticals, in collaboration with CRISPR Therapeutics and Boston Children's Hospital, to treat certain types of cystic fibrosis (CF) [1].
Cost Breakdown
The cost of Trikafta can be broken down into different components:
* The list price of Trikafta is around $295,000 per year for patients who weigh 50 kg or more.
* For patients weighing between 30 kg and 49 kg, the list price is around $250,000 per year.
* For patients weighing 20-29 kg, the list price is approximately $195,000 per year.
* For patients weighing less than 20 kg, the list price is around $140,000 per year.
Insurance Coverage and Patient Assistance Programs
While the list price of Trikafta may seem high, many patients are able to access the medication through insurance coverage, patient assistance programs, or Vertex's various financial assistance options. These programs can help reduce the out-of-pocket costs for patients or even provide free access to the medication for those who are eligible.
According to Vertex, patients have access to a variety of resources to help with the cost, including [2]:
* The Cystic Fibrosis Patient Assistance Program (CF PAP) to help with copays and coinsurance.
* The Cystic Fibrosis Vertex Commitment Program (CF VC) to provide free access to Trikafta for eligible patients.
* The Cystic Fibrosis Patient Access Program to help patients navigate insurance benefits.
* The Vertex Access to Care Team to help patients with coverage, payment, and other support services.
Generic Options and Competition
While Trikafta is still a novel medication, there are other cystic fibrosis treatments available. Research is ongoing to develop generic versions of Trikafta, which could potentially reduce costs for patients. However, the development and approval of generic versions of Trikafta can take several years.
Sources
[1] drugpatentwatch.com - Trikafta (Elexacaftor, Tezacaftor, Ivacaftor)
[2] Vertex Pharmaceuticals - Patient Resources
[3] American Lung Association - Cystic Fibrosis Treatment: Trikafta